Esperion to Participate in Upcoming Virtual Investor Conference
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
ANN ARBOR, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference.
| Event: | BTIG Virtual Biotechnology Conference |
| Date: | August 9, 2021 |
| Format: | Fireside Chat |
| Time: | 11:30 a.m. ET |
Live audio webcasts of these events can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replays of the webcasts will be archived on the Company's website for 90 days following the events.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Investor Contact:
Kaitlyn Brosco
Esperion
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
- ECN Launches ABM Matcher, Bringing Account-Based Marketing to Premium Office DOOH
- Southgobi Announces Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, BTIGSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share